Net Margin - Gland Pharma Ltd (NSE:GLAND)

Watchlist Manager

Watchlist

Price: 1 666.3 INR 0.82%

Market Cap: 274.5B INR

13.6%

Current

16%

Average

4.6%

Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin

13.6%

Net Income

7.9B

Revenue

58B

Net Margin Across Competitors

Country		Company	Market Cap	Net Margin
IN		Gland Pharma Ltd NSE:GLAND	274.5B INR	14%
US		Eli Lilly and Co NYSE:LLY	1T USD	31%
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	-4%
US		Johnson & Johnson NYSE:JNJ	507.7B USD	27%
CH		Roche Holding AG SIX:ROG	253.1B CHF	15%
UK		AstraZeneca PLC LSE:AZN	209B GBP	16%
CH		Novartis AG SIX:NOVN	206.8B CHF	26%
US		Merck & Co Inc NYSE:MRK	249.9B USD	30%
DK		Novo Nordisk A/S CSE:NOVO B	1.4T DKK	33%
IE	E	Endo International PLC LSE:0Y5F	209B USD	-126%
US		Pfizer Inc NYSE:PFE	142.8B USD	16%

Gland Pharma Ltd
Glance View

Economic Moat

None

Market Cap

274.5B INR

Industry

Pharmaceuticals

Gland Pharma Ltd., an Indian company with a robust heritage, has made its mark in the global pharmaceutical landscape primarily through its adeptness in injectable medication. Founded in 1978 by P.V.N. Raju, the company’s journey has been one of steady ascension, characterized by a firm commitment to quality and innovation. Operating in a market where precision and reliability are paramount, Gland Pharma has specialized in the development and manufacturing of complex generic injectables, a niche that demands rigorous regulatory compliance and state-of-the-art manufacturing capabilities. With its extensive product portfolio, Gland Pharma serves a diverse range of therapeutic areas, including anti-coagulants, anti-biotics, and anti-virus medications, catering to hospitals and healthcare facilities worldwide. This strategic focus has enabled the company to build a reputable name in both domestic and international markets, becoming a critical supplier in the intricate supply chain of modern healthcare. What distinguishes Gland Pharma from many contemporaries is its business model that hinges on backward integration and robust R&D capabilities. By taking charge of every aspect of production—from procuring raw materials to the final packaging—the company achieves cost efficiencies and ensures unwavering quality control. This integration extends beyond manufacturing, as Gland Pharma has cultivated strong relationships with strategic partners globally, facilitating its penetration into regulated markets such as the US, EU, and Australia. It harnesses these connections to distribute its products extensively while also acquiring ANDA (Abbreviated New Drug Application) approvals that cement its standing in these regions. Financially, Gland Pharma's revenue is largely derived from this steady export of generic injectables, riding on the ever-growing demand for affordable healthcare solutions. Through these strategic endeavors, the company encapsulates a blend of Indian manufacturing prowess and global pharmaceutical acumen, keeping its financial health robust and its market reach expansive.

View GLAND Analysis

GLAND Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

	Alpha Group International PLC LSE:ALPH	4 245.0001 GBX 0%
	Geojit Financial Services Ltd NSE:GEOJITFSL	79.15 INR -2.33%

	Johnson & Johnson NYSE:JNJ	210.315 USD -0.01%
	Berkshire Hathaway Inc NYSE:BRK.A	755 841.07 USD -0.04%
	Bank of America Corp NYSE:BAC	54.73 USD 0.33%
	Mastercard Inc NYSE:MA	567.23 USD 0.31%
	UnitedHealth Group Inc NYSE:UNH	328.135 USD -1.05%
	Exxon Mobil Corp NYSE:XOM	116.6101 USD -0.68%

	Franklin Covey Co NYSE:FC	16.83 USD 0.6%
	Mohawk Industries Inc NYSE:MHK	111.1 USD 1.74%
	Ardmore Shipping Corp NYSE:ASC	10.92 USD -1.97%
	ASGN Inc NYSE:ASGN	48.73 USD 2.05%
	Skyworks Solutions Inc NASDAQ:SWKS	65.31 USD 0.48%
	Weatherford International PLC NASDAQ:WFRD	77.12 USD -0.37%

	Johnson & Johnson NYSE:JNJ	210.315 USD -0.01%
	Bank of America Corp NYSE:BAC	54.73 USD 0.33%
	Mastercard Inc NYSE:MA	567.23 USD 0.31%
	Salesforce Inc NYSE:CRM	258.81 USD 0.26%
	Abbvie Inc NYSE:ABBV	225.11 USD 0.36%
	Home Depot Inc NYSE:HD	362.085 USD 1.5%

Gland Pharma Ltd
NSE:GLAND